Investigation of clinical factors influencing cognitive function in Japanese schizophrenia

Kishi, Taro; Moriwaki, Masatsugu; Kawashima, Koichiro; Okochi, Tomo; Fukuo, Yasuhisa; Kitajima, Tsuyoshi; Furukawa, Osamu; Naitoh, Hiroshi; Fujita, Kiyoshi; Iwata, Nakao

doi:10.1016/j.neures.2009.12.007

Cited by 23 publications

(19 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Replication of these findings in an independent large cohort or in different ethnic cohorts is needed. Second, several lines of evidence have indicated that cognitive performance in patients with schizophrenia is influenced by psychopharmacological medications [63,64]. In our positive finding of an association between rs713998 and executive function in patients with schizophrenia, we confirmed there was no significant difference ( P > 0.05) in the dosages of antipsychotics, anticholinergics, or the prescription status of anxiolytics/hypnotics under the dominant model.…”

Section: Discussionsupporting

confidence: 71%

Association of the Hermansky–Pudlak syndrome type 4 (HPS4) gene variants with cognitive function in patients with schizophrenia and healthy subjects

et al. 2013

View full text Add to dashboard Cite

BackgroundThe Hermansky–Pudlak Syndrome Type 4 (HPS4) gene, which encodes a subunit protein of the biogenesis of lysosome-related organelles complex (BLOC)-3, which is involved in late endosomal trafficking, is associated with schizophrenia; however, its clinical relevance in schizophrenia remains unknown. The purpose of the present study was to investigate whether HPS4 is associated with cognitive functions in patients with schizophrenia and healthy controls and with the clinical profiles of patients with schizophrenia.MethodsWe investigated the association of variants of HPS4 with clinical symptoms and cognitive function in Japanese patients with schizophrenia (n = 240) and age-matched healthy control subjects (n = 240) with single nucleotide polymorphisms (SNP)- or haplotype-based linear regression. We analyzed five tagging SNPs (rs4822724, rs61276843, rs9608491, rs713998, and rs2014410) of HPS4 and 2–5 locus haplotypes of these five SNPs. The cognitive functions of patients and healthy subjects were evaluated with the Brief Assessment of Cognition in Schizophrenia, Japanese-language version, and the patients were assessed for their symptomatology with the Positive and Negative Symptom Scale (PANSS).ResultsIn patients with schizophrenia, rs713998 was significantly associated with executive function under the dominant genetic model (P = 0.0073). In healthy subjects, there was a significant association between working memory and two individual SNPs under the recessive model (rs9608491: P = 0.001; rs713998: P = 0.0065) and two haplotypes (rs9608491-713998: P = 0.0025; rs61276843-9608491-713998: P = 0.0064). No significant association was found between HPS4 SNPs and PANSS scores or premorbid IQ, as measured by the Japanese version of the National Adult Reading Test.ConclusionsThese findings suggested the involvement of HPS4 in the working memory of healthy subjects and in the executive function deficits in schizophrenia.

show abstract

Section: Discussionsupporting

confidence: 71%

Association of the Hermansky–Pudlak syndrome type 4 (HPS4) gene variants with cognitive function in patients with schizophrenia and healthy subjects

et al. 2013

View full text Add to dashboard Cite

show abstract

“…This implies that the Tower of London test is less sensitive to cognitive deficit detection in schizophrenia. Furthermore, cognitive function has been associated with clinical symptoms or prescription of psychotropic drugs in patients with schizophrenia 34–36. The large deficits in motor speed and attention of schizophrenia patients may possibly be due to disease course or antipsychotic drug therapy.…”

Section: Discussionmentioning

confidence: 99%

Validation of the Chinese version of Brief Assessment of Cognition in Schizophrenia

Wang¹,

Lin²,

Yu³

et al. 2016

NDT

View full text Add to dashboard Cite

ObjectiveA test battery that measures cognitive function impairment in patients with schizophrenia, the Brief Assessment of Cognition in Schizophrenia (BACS), has been translated into various languages and validated. This study aimed to test the reliability and validity of the Chinese version of the BACS in a Chinese-speaking population.MethodsAll participants in this study (66 patients with schizophrenia [mean age: 41.2 years, 57.6% male] and 66 age- and sex-matched healthy controls) were from Taiwan and assessed using the BACS and the University of California, San Diego (UCSD) Performance-Based Skills Assessment, Brief Version (UPSA-B). Thirty-eight of the 66 patients with schizophrenia received a reassessment using the BACS.ResultsThe BACS had good test–retest reliability, and all BACS subtests had statistically insignificant practice effects. Principal components analysis demonstrated that a one-factor solution best fits our dataset (60.9% of the variance). In both patients and controls, the BACS composite scores were positively correlated with all BACS subscales (P<0.001) and UPSA-B scales (P<0.001). Furthermore, all BACS subtests (verbal memory, working memory, motor speed, verbal fluency, attention and processing speed, and executive function) significantly differentiated patients with schizophrenia from healthy controls (P<0.001), and the BACS composite score had the best discriminative validity (P<0.001).ConclusionThe Chinese version of the BACS exhibits satisfactory psychometric properties, including high test–retest reliability, high internal consistency, acceptable concurrent validity, and good discriminant validity. We suggest that the BACS is a reliable and practical tool for assessing cognitive function in patients with schizophrenia.

show abstract

“…These domains include the executive functions, perceptual and motor processing, attentional skills, vigilance, verbal learning and memory, spatial working memory, and verbal fluency [1]–[2]. These deficits are considered core symptoms of the schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

Effect of Aripiprazole on Mismatch Negativity (MMN) in Schizophrenia

2013

View full text Add to dashboard Cite

BackgroundCognitive deficits are considered core symptoms of the schizophrenia. Cognitive function has been found to be a better predictor of functional outcome than symptom levels. Changed mismatch negativity (MMN) reflects abnormalities of early auditory processing in schizophrenia. Up to now, no studies for the effects of aripiprazole on MMN in schizophrenia have been reported.Methodology/Principal FindingsSubjects included 26 patients with schizophrenia, and 26 controls. Psychopathology was rated in patients with the Positive and Negative Syndrome Scale (PANSS) at baseline, after 4- and 8-week treatments with aripiprazole. Auditory stimuli for ERP consisted of 100 millisecond/1000 Hz standards, intermixed with 100 millisecond/1500 Hz frequency deviants and 250 millisecond/1000 Hz duration deviants. EEG was recorded at Fz. BESA 5.1.8 was used to perform data analysis. MMN waveforms were obtained by subtracting waveforms elicited by standards from waveforms elicited by frequency- or duration-deviant stimuli. Aripiprazole decreased all PANSS. Patients showed smaller mean amplitudes of frequency and duration MMN at baseline than did controls. A repeated measure ANOVA with sessions (i.e., baseline, 4- and 8-week treatments) and MMN type (frequency vs. duration) as within-subject factors revealed no significant MMN type or MMN type × session main effect for MMN amplitudes. Session main effect was significant. LSD tests demonstrated significant differences between MMN amplitudes at 8 weeks and those at both baseline and 4 weeks. There was significant negative correlation between changes in amplitudes of frequency and duration MMN and changes in PANSS total scores at baseline and follow-up periods.ConclusionsAripiprazole improved the amplitudes of MMN. MMN offers objective evidence that treatment with the aripiprazole may ameliorate preattentive deficits in schizophrenia.

show abstract

Investigation of clinical factors influencing cognitive function in Japanese schizophrenia

Cited by 23 publications

References 19 publications

Association of the Hermansky–Pudlak syndrome type 4 (HPS4) gene variants with cognitive function in patients with schizophrenia and healthy subjects

Association of the Hermansky–Pudlak syndrome type 4 (HPS4) gene variants with cognitive function in patients with schizophrenia and healthy subjects

Validation of the Chinese version of Brief Assessment of Cognition in Schizophrenia

Effect of Aripiprazole on Mismatch Negativity (MMN) in Schizophrenia

Contact Info

Product

Resources

About